Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Polymorphisms in genes of the steroid receptor superfamily modify postmenopausal breast cancer risk associated with menopausal hormone therapy.

International journal of cancer - 15 Jun 2010

Abstract excerpt

Menopausal hormone therapy (HT) is associated with increased breast cancer risk among postmenopausal women. Nuclear receptors are involved in steroid hormone- and xenobiotic-mediated signal transduction playing a crucial role in regulating gene expression. Therefore, variations within these genes may influence HT-associated breast cancer risk. We investigated 3,149 postmenopausal breast cancer patients and 5,489...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Estrogen Receptor alpha
Share to Estrogen Receptor beta
Share to Hormone Replacement Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Menopause

Share to Peroxisome-Targeting Signal 1 Receptor

Share to Receptors, Androgen

Share to Receptors, Cytoplasmic and Nuclear

Share to Survival Rate

Source

Identifiers

PMID: 19739075
DOI: 10.1002/ijc.24892

Genes

ESR1
ESR2
PGR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Polymorphisms in genes of the steroid receptor superfamily modify postmenopausal breast cancer risk associated with menopausal hormone therapy.PMID 19739075Read ↗

Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women.Semantic proximity Read ↗

Polymorphism Thr160Thr in SRD5A1, involved in the progesterone metabolism, modifies postmenopausal breast cancer risk associated with menopausal hormone therapy.Semantic proximity Read ↗

Postmenopausal estrogen monotherapy-associated breast cancer risk is modified by CYP17A1_-34_T>C polymorphism.Semantic proximity Read ↗

Polymorphisms in genes involved in sex hormone metabolism, estrogen plus progestin hormone therapy use, and risk of postmenopausal breast cancer.Semantic proximity Read ↗

Variations in sex hormone metabolism genes, postmenopausal hormone therapy and risk of endometrial cancer.Semantic proximity Read ↗

Mutations and polymorphisms of estrogens receptors genes and diseases susceptibility.Semantic proximity Read ↗

Influence of estrogen receptor alpha and progesterone receptor polymorphisms on the effects of hormone therapy on mammographic density.Semantic proximity Read ↗

Estrogen receptor beta genetic variants and combined oral contraceptive use as relates to the risk of hypertension in Chinese women.Semantic proximity Read ↗

Estrogen metabolism genotypes, use of long-term hormone replacement therapy and risk of postmenopausal breast cancer.Semantic proximity Read ↗

Pharmacogenetic modulation of combined hormone replacement therapy by progesterone-metabolism genotypes in postmenopausal breast cancer risk.Semantic proximity Read ↗

A systematic review of the relationship between polymorphic sites in the estrogen receptor-beta (ESR2) gene and breast cancer risk.Semantic proximity Read ↗

Estrogen receptor polymorphisms and the risk of endometrial cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.